REFERENCES
- Baker WC, Russo MA, De Vere White RW, Severe bladder contracture in patient receiving intravesical Mitomycin C for superficial bladder cancer. Urology 1987; 30: 357–358.
- Crawford D, McKenzie D, Månsson W, Totonchy M, Grossman B, Davis M, Lamm D, Duchek M, Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases, J Urol 1987; 136: 668–669.
- Droller MJ, Walsh PS, Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe? J Urol 1985; 134: 1115–1117.
- Ek A, Hellsten S, Henrikson HI, Idvall I, Lindholm C-E, Lindholm K, Mikulowski P, Månsson W, Intravesical Adriamycin therapy in carcinoma in situ of the urinary bladder, Scand J Urol Nephrol 1984; 18 131–134.
- Eksborg S, Nilsson S-O, Edsmyr F, Intravesical instillation of adriamycin, A model for standardization of the chemotherapy, Eur Urol 1980; 6: 218–220.
- Herr HW, WhitmoreJr WF, Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management, J Urol 1987; 138: 292–294.
- Issell BF, PeroutJr GR, Soloway MS, Cummings KB, Brannen G, Veenema R, Flanagan M, Block NL, Summers JL, Levin EA, Defuria MD, Mitomycin C intravesical therapy in noninvasive bladder cancer after failure of thiotepa, Cancer 1984; 53: 1025–1028.
- Jauhiainen K, Eksborg S, Kangas L, Perilä M, Alfthan O, The absorption of Doxorubicin and Mitomycin C in perioperative instillation, Eur Urol 1985; 11: 269–272.
- Jauhiainen K, Sotarauta M, Permi J, Alfthan O, Effect of Mitomycin C and Doxorubicin instillation on carcinoma in situ of the urinary bladder, Eur Urol 1986; 12: 32–37.
- Jenkins BJ, England HR, Fowler CG, Tiptaft RC, Badenock DF, Paris AMI, Oliver RTF, Blandy JP, Chemotherapy for carcinoma in situ of the bladder, Br J Urol 1988; 61: 326–329.
- Mahadevia PS, Koss LG, Tar IJ, Prostatic involvement in bladder cancer, Prostate mapping of 20 cystoprostatectomy specimens, Cancer 1986; 58: 2096–2102.
- Melicow MM, Hollowell JW, Intraurothelial cancer, carcinoma in situ, Bowen's disease of the urinary system: discussion of thirty cases, J Urol 1952; 68: 763–772.
- Mostofi FK, Sobin LH, Toloni H, Histological typing of urinary bladder tumours, World Health Organization, Geneva, 1973.
- ProutJr GR, Griffin PP, Daly JJ, The outcome of conservative treatment of carcinoma in situ of the bladder, J Urol 1987; 138: 766–770.
- Soloway MS, Rationale for intensive intravesical chemotherapy for superficial urinary bladder cancer, J Urol 1980; 123: 461–466.
- Soloway MS, Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients, J Urol 1985; 134: 1107–1109.
- Soloway MS, Ford KS, Thio-tepa-induced myelosuppression: review of 670 bladder instillations, J Urol 1983; 133: 889–891.
- Stanisic TH, Donovan JM, Lebouton J, Graham AR, 5-year experience with intravesical therapy of carcinoma in situ: an inquiry into the risks of “conservative” management, J Urol 1987; 138: 1158–1161.
- Stricker PD, Grant ABF, Hosken BM, Taylor JS, Topical Mitomycin C therapy for carcinoma of the bladder, J Urol 1987; 138: 1164–1166.
- UICC International Union against Cancer. TNM classification of malignant tumours, 4th ed, Berlin: Springer-Verlag, 1987.
- Wajsman Z, Dhafir RA, Pfeffer M, MacDonald S, Block A, Dragone N, Pontes JE, Studies of Mitomycin C absorption after intravesical treatment of superficial bladder tumours, J Urol 1984; 132: 30–33.
- Wolf H, Hôjgaard K, Urothelial dysplasia in random mucosal biopsies from patients with bladder tumours, Scand J Urol Nephrol 1980; 14: 37–41.
- Zincke H, Utz DC, Farrow GM, Review of Mayo Clinic experience with carcinoma in situ, Urology 1985; 26: 39–46.